Table 2 Mechanism and drug resistance of m⁶A regulatory factor in related tumors

Breast cancer

METTL3

Oncogene

In vitro: MCF-7

METTL3, hepatitis B virus X protein binding protein (HBXIP) and miRNA let-7 g form a positive feedback loop

Tamoxifen

[41]

ALKBH5

Oncogene

In vivo: mice

Demethylation of NANOG and increase of mRNA level

[42]

Ovarian cancer

YTHDF1

Oncogene

In vitro: SKOV3, A2780

TRIM29 may be used as an oncogene

Cisplatin

[43]

FTO/ALKBH5

Oncogene

In vitro: PEO1

Up-regulation of Wnt/ β-catenin pathway by stabilizing FZD1

Olaparib

[44]

Cervical cancer

FTO

Oncogene

In vitro: SiHa

Regulation of β-catenin/ERCC1 axis

–

[45]

Acute myeloid leukemia (AML)

METTL3

Oncogene

In vitro: MOLM13, THP-1, MV4-11, NOMO-1, HL-60, EOL-1, KG-1, RN2c, HEL, JURKA T, LOUCY, K562

Regulating the expression of c-Myc, Bcl-2 and PTEN

–

[46]

METTL14

Oncogene

In vivo: human

Enhanced self-renewal of hematopoietic stem cells and inhibition of bone marrow cell differentiation through SPI1-METTL14-MYB/MYC axis

–

[47]

WTAP

Oncogene

In vitro: K562,HL-60,OCI-AML3,Ba/F3

Regulating WT1 pathway to promote cell proliferation

–

[48]

Glioblastomas (GBMs)

METTL3

Oncogene

In vivo: human

Inhibition of tumorigenesis and self-renewal / proliferation of MSCs

Y- Irradiation

[49]

METTL14

Suppressor

In vivo: human

It is possible to target ADAM19 to inhibit tumorigenesis and self-renewal / proliferation of glioma stem-like cells (GSCs)

–

[50]

FTO

Oncogene

In vivo: human

The inhibitory effect of drugs on FTO can inhibit the formation of m⁶A demethylation gene in glioblastoma

–

[50]

ALKBH5

Oncogene

In vivo: mice

Demethylated FOXM1 promotes tumorigenicity of GSC

–

[51]

Non-small cell lung cancer

(NSCLC)

METTL3

Oncogene

In vitro: A549, H1299, Calu6,H520,95-D, PC9,HCC827

SUMO promotes tumor growth of lysine residues K177, K211, K212 and K215 in NSCLC

Cisplatin/

Gefitinib

[52, 53]

WTAP

Oncogene

In vitro: H1299, A549, EBC-1, HCC827,CALU-3, H661,H596, H358, H460,H1650, H1975, H1395,H292

Down-regulation of c-MET expression

Crizotinib

[54]

YTHDF1

Suppressor

In vitro: HEK-293T, H1975, A549, NCI-H838, H1299, NCI-H1650,GLC-82, SPC-A1

regulating the translational efficiency of CDK2, CDK4, and cyclin D1

Cisplatin

[55]

Hepatocellular cance

METTL3

Oncogene

In vitro: HepG2,Huh-7,MHCC97L, HepG-2,Hepa1-6, HEK-293T,WRL68, HUVEC,SMMC-7721, Bel7402,HepG-2, WRL68, HEK-293T

Reduce the stability of SOCS2 mRNA

Sorafenib

[56, 57]

METTL14

Oncogene

In vivo: mice

Progress in regulating miR-126 through DGCR8

Sorafenib

[58]

YTHDF2

Oncogene

In vitro: HepG2,293T

MiR-145 regulates m⁶A level by targeting YTHDF2 mRNA 3-UTR in hepatocellular carcinoma cells

–

[59]

Gastric cancer

METTL3

Suppressor

In vitro: AGS,HGC-27, MKN-45

mediated this process occurred on the A879 locus of pri-miR-17-92

Everolimus

[60]

Colorectal cancer

YTHDF1

Oncogene

In vitro: SW480,CaCO2, HT29, RKO,DLD-1, KM12SM, HCT-116,LoVo

C-Myc promotes the expression of YTHDF1 and affects the proliferation and chemosensitivity of colorectal cancer

Oxaliplatin/ 5-Fu

[61]

Pancreatic cancer

METTL3

Oncogene

In vitro: MIA PaCa-2

METTL3 is associated with mitogen-activated protein kinase cascades, ubiquitin-dependent process and RNA splicing and regulation of cellular process

Cisplatin/

Fu /

Y-Irradiation

[62]